Literature DB >> 19074825

The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Jill Wykosky1, Waldemar Debinski.   

Abstract

The Eph receptor tyrosine kinases and ephrin ligands have been studied extensively for their roles in developmental processes. In recent years, Eph receptors and ephrins have been found to be integral players in cancer formation and progression. Among these are EphA2 and ephrinA1, which are involved in the development and maintenance of many different types of solid tumors. The function of EphA2 and ephrinA1 in tumorigenesis and tumor progression is complex and seems to be dependent on cell type and microenvironment. These variables affect the expression of the EphA2 and ephrinA1 proteins, the pathways through which they induce signaling, and the functional consequences of that signaling on the behavior of tumor cells and tumor-associated cells. This review will specifically focus on the roles that EphA2 and ephrinA1 play in the different cell types that contribute to the malignancy of solid tumors, with emphasis on the opportunities for therapeutic targeting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074825      PMCID: PMC3690928          DOI: 10.1158/1541-7786.MCR-08-0244

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  141 in total

Review 1.  The ephrins and Eph receptors in angiogenesis.

Authors:  Nikki Cheng; Dana M Brantley; Jin Chen
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

2.  Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours.

Authors:  Dong Li Guo; Ji Zhang; Siu Tsan Yuen; Wai Yin Tsui; Annie S Y Chan; Coral Ho; Jiafu Ji; Suet Yi Leung; Xin Chen
Journal:  Carcinogenesis       Date:  2005-11-04       Impact factor: 4.944

3.  A conditional feedback loop regulates Ras activity through EphA2.

Authors:  Madhu Macrae; Richard M Neve; Pablo Rodriguez-Viciana; Christopher Haqq; Jennifer Yeh; Chira Chen; Joe W Gray; Frank McCormick
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

4.  Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.

Authors:  Shaji Abraham; Deborah W Knapp; Liang Cheng; Paul W Snyder; Suresh K Mittal; Dinesh S Bangari; Michael Kinch; Lan Wu; Jay Dhariwal; Sulma I Mohammed
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Authors:  Christopher J Herrem; Tomohide Tatsumi; Kathleen S Olson; Keisuke Shirai; James H Finke; Ronald M Bukowski; Ming Zhou; Amy L Richmond; Ithaar Derweesh; Michael S Kinch; Walter J Storkus
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

6.  Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.

Authors:  Kelly Carles-Kinch; Katherine E Kilpatrick; Jane C Stewart; Michael S Kinch
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

7.  Characterization of a novel Src-like adapter protein that associates with the Eck receptor tyrosine kinase.

Authors:  A Pandey; H Duan; V M Dixit
Journal:  J Biol Chem       Date:  1995-08-18       Impact factor: 5.157

8.  Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.

Authors:  Nicole K Noren; Mark Lu; Andrew L Freeman; Mitchell Koolpe; Elena B Pasquale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

9.  Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling.

Authors:  Isobel D Lawrenson; Sabine H Wimmer-Kleikamp; Peter Lock; Simone M Schoenwaelder; Michelle Down; Andrew W Boyd; Paul F Alewood; Martin Lackmann
Journal:  J Cell Sci       Date:  2002-03-01       Impact factor: 5.285

10.  Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Authors:  Manabu Hatano; Naruo Kuwashima; Tomohide Tatsumi; Jill E Dusak; Fumihiko Nishimura; Karlyne M Reilly; Walter J Storkus; Hideho Okada
Journal:  J Transl Med       Date:  2004-11-24       Impact factor: 5.531

View more
  147 in total

1.  Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer.

Authors:  Joseph A Sparano; Lori J Goldstein; Barrett H Childs; Steven Shak; Diana Brassard; Sunil Badve; Frederick L Baehner; Roberto Bugarini; Steve Rowley; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson; Paraic A Kenny; George W Sledge; Robert Gray
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

2.  The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirus.

Authors:  Alexander S Hahn; Johanna K Kaufmann; Effi Wies; Elisabeth Naschberger; Julia Panteleev-Ivlev; Katharina Schmidt; Angela Holzer; Martin Schmidt; Jin Chen; Simone König; Armin Ensser; Jinjong Myoung; Norbert H Brockmeyer; Michael Stürzl; Bernhard Fleckenstein; Frank Neipel
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

3.  EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.

Authors:  Arend H Sikkema; Wilfred F A den Dunnen; Esther Hulleman; Dannis G van Vuurden; Guillermo Garcia-Manero; Hui Yang; Frank J G Scherpen; Kim R Kampen; Eelco W Hoving; Willem A Kamps; Sander H Diks; Maikel P Peppelenbosch; Eveline S J M de Bont
Journal:  Neuro Oncol       Date:  2012-06-21       Impact factor: 12.300

Review 4.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

5.  Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation.

Authors:  Xiao-Yi Yang; Wei-Jie Zhu; Huan Jiang
Journal:  Mol Cell Biochem       Date:  2011-10-19       Impact factor: 3.396

6.  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Authors:  Vassiliki Kotoula; Sofia Lambaki; Despina Televantou; Anna Kalogera-Fountzila; Angelos Nikolaou; Konstantinos Markou; Despina Misailidou; Konstantinos N Syrigos; George Fountzilas
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

Review 7.  Therapeutic targeting of EPH receptors and their ligands.

Authors:  Andrew W Boyd; Perry F Bartlett; Martin Lackmann
Journal:  Nat Rev Drug Discov       Date:  2014-01       Impact factor: 84.694

Review 8.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

9.  Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Authors:  J Jehle; I Staudacher; F Wiedmann; Pa Schweizer; R Becker; Ha Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

10.  EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts.

Authors:  Elisa Giannoni; Maria Letizia Taddei; Matteo Parri; Francesca Bianchini; Michela Santosuosso; Renata Grifantini; Gabriella Fibbi; Benedetta Mazzanti; Lido Calorini; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2012-08-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.